3
Indication details
- Control Arm
- Single arm
- Therapeutic Indication
- Treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum containing therapy
- Tumour Type
-
Genitourinary Cancers
- Tumour Sub-type
- Urothelial Carcinoma
- Tumour Stage
- Locally advanced unresectable or metastatic
- Trial Name
- CheckMate 275
- NCT Number
- NCT02387996
- Trial Phase
- Phase II
Approval details
- FDA Approval
- FDA approval February 2017
- EMA Approval
- EMA (CHMP) April 2017 EC decision June 2017
Primary Outcome(s)
- Primary Outcome(s)
- ORR (Overall)
- Evaluated Outcome
- ORR
- Form(s)
- Form 3
Outcome Data
- PFS Control
- 1.9 months
- ORR
- 20.7%
- DoR
- 20.3 months
Adjustments
- QoL Comment
-
QoL was an exploratory endpoint
Score (after adjustments)
- Preliminary non-curative score
-
3
- Non-curative score
-
3
Scorecard details
- ESMO-MCBS version
- ESMO-MCBS v1.1
- Scorecard ID
- 240
- Scorecard version
- 1
- Issue date
- 01.03.2021
- Last update
- 21.12.2023
Legend
Information about symbols, abbrevations and color codes
- DFS
- Disease-Free Survival
- DoR
- Duration of Response
- EFS
- Event-Free Survival
- HR
- Hazard Ratio
- NEB
- No evaluable benefit
- NI
- Non-inferiority Study
- ORR
- Overall Response Rate
- OS
- Overall Surival
- pCR
- Pathological Complete Response/Remission
- PFS
- Progression-Free Survival
- QoL
- Quality of Life
- RFS
- Relapse-Free Survival
- RR
- Response Rate
QoL adjustments
Other adjustments*
Serious and disabling adverse effects
Red = negative / deterioration
Green = positive / improvement
Red = negative / deterioration
Green = positive / improvement
Red = negative / deterioration
Green = positive / improvement
Red = negative / deterioration
Green = positive / improvement
* Other adjustments include: